Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 30 2014
Print

Breaking News

Related Searches: Pharma Development Biopharma CRO
September 29, 2014
Expands gene-editing capabilities  Read More »
September 29, 2014
Gains Phase III AML candidate quizartinib  Read More »
September 29, 2014
Gains drug candidates and a 500,000 compound CNS-focused, small-molecule library  Read More »
September 29, 2014
Expands therapeutic offerings and Asia-Pac reach  Read More »
September 26, 2014
Forms executive committee   Read More »
September 26, 2014
Will sell Captisol-enabled formulation to Merck   Read More »
September 26, 2014
NP-RD20, an R&D style tablet press, and the NP-155 rotary tablet press  Read More »
September 25, 2014
Previously marketed products will enter $200 million U.S. market  Read More »
September 25, 2014
Sees growth in small molecule discovery technology  Read More »
September 25, 2014
Will align conjugation and manufacture of drug linkers with sterile fill/finish services  Read More »
September 25, 2014
Houses 6,000 sq.-ft. dedicated to microbiological testing and bioanalytical services  Read More »
September 24, 2014
PBOA to represent CMO/CDMO interests  Read More »
September 24, 2014
Baxter gains ex-U.S. rights to Phase III, orphan pancreatic cancer drug  Read More »
September 24, 2014
Aims to develop a gene therapy to treat rare genetic disease  Read More »
September 24, 2014
ADHD drugs will employ Catalent’s OSDrC OptiDose drug delivery platform  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On